Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
Investigational New Drugs
|
June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation
Capucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
BMJ Supportive & Palliative Care
|
August 30, 2022
PALLIA 10 score in phase I cancer studies
Kaïssa Ouali, Christine Mateus, Arianne Laparra, et al.
Oncotarget
|
March 9, 2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
Luc Cabel, Alina Fuerea, Ludovic Lacroix, et al.
Drugs & Aging
|
May 15, 2025
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials
Ana Vaz Ferreira, Matthieu Delaye, Arnaud Pages, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2018
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, et al.
Critical Reviews in Oncology/Hematology
|
November 25, 2023
Antibody drug conjugates in older patients: State of the art
Layal Rached, Arthur Geraud, Maxime Frelaut, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 22, 2022
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials
Capucine Baldini, Nadia Younan, Eduardo Castanon Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Mark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
Investigational New Drugs
|
June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation
Capucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
BMJ Supportive & Palliative Care
|
August 30, 2022
PALLIA 10 score in phase I cancer studies
Kaïssa Ouali, Christine Mateus, Arianne Laparra, et al.
Oncotarget
|
March 9, 2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
Luc Cabel, Alina Fuerea, Ludovic Lacroix, et al.
Drugs & Aging
|
May 15, 2025
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials
Ana Vaz Ferreira, Matthieu Delaye, Arnaud Pages, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2018
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, et al.
Critical Reviews in Oncology/Hematology
|
November 25, 2023
Antibody drug conjugates in older patients: State of the art
Layal Rached, Arthur Geraud, Maxime Frelaut, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 22, 2022
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials
Capucine Baldini, Nadia Younan, Eduardo Castanon Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Mark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
Page
of 11